Novel therapeutics for portal hypertension and fibrosis in chronic liver disease

Sergi Guixé-Muntet; Chang-Peng Zhu; Wei-Fen Xie; Jordi Gracia-Sancho

doi:10.1016/j.pharmthera.2020.107626

Novel therapeutics for portal hypertension and fibrosis in chronic liver disease

Pharmacol Ther. 2020 Nov:215:107626. doi: 10.1016/j.pharmthera.2020.107626. Epub 2020 Jul 11.

Authors

Sergi Guixé-Muntet¹, Chang-Peng Zhu², Wei-Fen Xie², Jordi Gracia-Sancho³

Affiliations

¹ Hepatology, Department of Biomedical Research, Inselspital & University of Bern, Switzerland.
² Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
³ Hepatology, Department of Biomedical Research, Inselspital & University of Bern, Switzerland; Liver Vascular Biology Research Group, Barcelona Hepatic Hemodynamic Unit, IDIBAPS, CIBEREHD, Barcelona, Spain. Electronic address: jordi.gracia@idibaps.org.

PMID: 32659305
DOI: 10.1016/j.pharmthera.2020.107626

Abstract

Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver disease, determining clinical complications that lead to death or liver transplantation. PH results from increased resistance to portal blood flow through the cirrhotic liver, which is due to hepatic fibrosis and microcirculatory dysfunction. The present review focuses on the pathophysiology of fibrosis and PH, describes currently used treatments, and critically discusses potential therapeutic options.

Keywords: Cirrhosis; Hepatic hemodynamic; Hepatic stellate cells; Liver microcirculation; Portal pressure.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Chronic Disease
Humans
Hypertension, Portal / etiology
Hypertension, Portal / physiopathology
Hypertension, Portal / therapy*
Liver Cirrhosis / complications*
Liver Cirrhosis / physiopathology
Liver Diseases / complications*
Liver Diseases / physiopathology